| ￥4100 | |
| Z04202-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. Measured by its ability to hydrolyze the 5'phosphate groups from the substrate adenosine5'triphosphate (ATP).Test result meets the standard. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 51.91 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22 μm filtered solution in 20mM Tris, 150mM NaCL (pH 8.0). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | CD39, also known as ENTPD1, belongs to the GDA1/CD39 NTPase family. It is expressed primarily on activated lymphoid cells and can also be detected in endothelial tissues.CD39 is involved in the processes of thromboregulation and vascular inflammation. The administration of soluble NTPDase-1 may have therapeutic applications for the treatment of some vascular and transplantation-associated diseases . |
| Synonyms | CD39; NTPD1; NTPDase 1; ADPase; ATPDase; DKFZp686D194; DKFZp686I093; EC 3.6.1; ENTPD1; FLJ40921; FLJ40959; SPG64 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
